IMNM: Rega marang dodolan Immunome Inc
Immunome, Inc. (IMNM) development of targeted antibodies remains independent of market cycles, as confirmed by the current P/S multiple. The value 741.00 establishes a new valuation benchmark. The business relies on partner payments prior to the market launch of oncology drugs. Risks are limited to standard biohazardous waste disposal controls, ensuring the company's baseline environmental compliance.
Immunome Corp (IMNM) - rincian metrik lan laporan keuangan
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Immunome, Inc.|IMNM - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Immunome Bio|IMNM - Utang perusahaan|Rasio utang marang nilai buku Immunome Corp|IMNM - Utang jangka dawa perusahaan|Utang jangka cendhak Immunome|Indikator likuiditas cepet immunome.com
- data bathi resik lan rasio valuasi:
IMNM - Bathi resik|Bathi resik sing dikarepake Immunome, Inc.|IMNM - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Immunome Inc|IMNM - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Immunome Corp|IMNM - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Immunome|IMNM - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan immunome.com|IMNM - Wutah bathi resik saben saham ing taun iki|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Immunome, Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:immunome.com (IMNM)
The ratio of market capitalization to annual revenue determines the investment value per unit of turnover, reflecting the current market interpretation of the business's value. The P/S multiple dynamics for Immunome, Inc. (IMNM) allow for an assessment of the company's valuation adequacy relative to the pace of milestone achievements and the efficiency of its cash burn, which is critical for a biotech firm in the development phase of targeted conjugates.
Pesaing Immunome, Inc.
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|Koefisien rega marang pendapatan Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan kiniksa.com|Rasio rega marang pendapatan Grifols|Kapitalisasi marang pendapatan Adaptive Biotech (ADPT)|Kapitalisasi marang pendapatan CLDX (Celldex)|Multiplikator P/S Aurinia Corp (AUPH)|Rasio rega marang pendapatan BioCryst BCRX|VERA: Rasio kapitalisasi marang pendapatan|DNTH - Rasio rega marang pendapatan|Rega marang dodolan Pharvaris NV|AbCellera Biologics Inc (ABCL) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Tourmaline|PGEN (Precigen, Inc.) - Multiplikator P/S|Rega marang dodolan pharming.com PHAR|Kapitalisasi marang pendapatan NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ZBIO (Zenas Biopharma, Inc.)|Koefisien rega marang pendapatan Gossamer Bio Corp. (GOSS)|KALV - Rasio rega marang pendapatan|SEPN (septerna.com) - Rasio kapitalisasi marang pendapatan|PVLA: Multiplikator P/S|Kapitalisasi marang pendapatan Savara Inc|Kapitalisasi marang pendapatan RIGL|AnaptysBio Inc. (ANAB) - Koefisien rega marang pendapatan|Multiplikator P/S ATXS|Koefisien rega marang pendapatan engene.com|Rasio rega marang pendapatan RAPT Therapeutics RAPT|JBIO - Kapitalisasi marang pendapatan|ACRS - Rasio rega marang pendapatan|KYTX (Kyverna Therapeutics, Inc) - Rasio kapitalisasi marang pendapatan|Tiziana Life Sciences (TLSA) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan cabalettabio.com|Rasio rega marang pendapatan Ventyx Biosciences, Inc.|Theratechnologies, Inc. - Rasio rega marang dodolan|Multiplikator P/S AVTX|ELDN (Eledon Pharmaceuticals, Inc) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S AGEN (Agenus)|Multiplikator P/S climbbio.com CLYM|ZURA - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ATYR (aTyr Pharma Inc)|adagene.com (ADAG) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Ikena Oncology|STTK (Shattuck Labs Inc) - Multiplikator P/S|Multiplikator P/S Equillium Bio|Kapitalisasi marang pendapatan CNTB (Connect Biopharma)|IMUX (immunic-therapeutics.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ATRA (Atara Bio)|Koefisien rega marang pendapatan InflaRx NV (IFRX)|XFOR - Rasio rega marang pendapatan|Adicet Bio (ACET) - Kapitalisasi marang pendapatan|celularity.com (CELU) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan INmune Bio Inc|Kapitalisasi marang pendapatan BRNS|Multiplikator P/S Kezar Life Sciences Inc|Rasio rega marang pendapatan SAB Biotherapeutics (SABS)|akaritx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Rega marang dodolan|GeoVax Labs Inc - Multiplikator P/S|Koefisien rega marang pendapatan Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Carisma Therapeutics Inc.|Rasio rega marang pendapatan XTL Biopharmaceuticals Ltd.|Kapitalisasi marang pendapatan Bolt Bio (BOLT)|Kapitalisasi marang pendapatan HCWB (HCW Biologics Inc.)|Multiplikator P/S aptevotherapeutics.com (APVO)|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX: Rasio kapitalisasi marang pendapatan|GRI - Rasio rega marang pendapatan|Rega marang dodolan XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Revelation Biosciences Corp|INDP (Indaptus Therapeutics) - Multiplikator P/S|Rega marang dodolan scinai.com SCNI|Kapitalisasi marang pendapatan CALI (CalciMedica, Inc.)|AFMD (affimed.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALLK (Allakos)|Koefisien rega marang pendapatan HOOKIPA Pharma, Inc. (HOOK)|IGMS - Rasio rega marang pendapatan|ITOS (iteostherapeutics.com) - Rasio kapitalisasi marang pendapatan|OCEA: Multiplikator P/S|Kapitalisasi marang pendapatan TC BioPharm (Holdings) Plc|Kapitalisasi marang pendapatan THRD
